MedTrace Logo

Statin Contrast Induced Nephropathy Prevention

NCT01185938 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 500

Last updated 2012-10-19

No results posted yet for this study

Summary

This open-label study, prospective, randomized trial evaluating the acute (in-hospital) pleiotropic and clinical effects of a hydrophilic statin (rosuvastatin) in patients with acute coronary syndrome

Conditions

  • Acute Coronary Syndrome

Interventions

DRUG

Rosuvastatin

One oral single dose of rosuvastatin of 40 mg at admission and then 20 mg/day for 1 month.

Sponsors & Collaborators

  • Centro Cardiopatici Toscani

    lead OTHER

Principal Investigators

  • Anna Toso, MD · Misericordia e Dolce, Prato Hospital, Cardiology Unit

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-07-31
Primary Completion
2012-09-30
Completion
2012-10-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01185938 on ClinicalTrials.gov